The authors concluded that GRPr and PSMA-based imaging may have a complimentary role to fully characterize prostate cancer disease, GRPr being targeted in low-metastatic-risk patients while PSMA could be a valuable target in higher risks. The gene discussed is FOLH1; the disease is prostate carcinoma.